Screener / SEC EDGAR /CIK 0001819790 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Tarsus Pharmaceuticals, Inc. TARS

Compare with peers Embed
FY2025 at a glance

Sales up 146.7%, free cash flow up to -$22.3M

XBRL, from each 10-K
RevenueStatements
$451.4M from $183.0M in FY2024
FY2018FY2025
Net incomeStatements
-$66.4M from -$115.6M in FY2024
FY2018FY2025
Free cash flowStatements
-$22.3M from -$84.6M in FY2024
FY2018FY2025
EPS (diluted)Statements
$-1.59 from $-3.07 in FY2024
FY2018FY2025
Operating marginStatements
-15.7% from -65.9% in FY2024
FY2018FY2025
Total debtStatements
$72.4M from $71.8M in FY2024
FY2018FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (35)
EPS (ttm)
-15.86
Sales (ttm)
682.2M
Net income (ttm)
-702.2M
Sales growth
+147%
EPS growth
-
Sales Q/Q
+63.9%
Free cash flow
32.4M
Gross margin
-
Oper. margin
-102.0%
Net margin
-102.9%
FCF margin
4.8%
ROE
n/m
R&D / sales
14.3%
Dividend
0.00
Debt/Eq
0.70
Curr. ratio
1.96
Cash
136.5M
Op. cash flow (ttm)
49.9M
EBITDA
-70.1M
EBITDA margin
-15.5%
Net debt
-63.6M
Quick ratio
1.94
Interest cover
-7.94
FCF after stock pay
-64.0M
Oper. margin low 5y
-820.5%
Stock pay / sales
9.2%
Shares out.
49.3M
Shares Y/Y
+11.1%
Book / share
2.11
Cash / share
2.77
Sales / share
13.84
Asset turnover
1.35
Days sales out.
69
Sales 3Y CAGR
+159%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2020 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 451.4M Net income -66.4M
FY2020 revenue 0 · Revenues, 0001819790-22-000010 FY2020 net income -26.8M · NetIncomeLoss, 0001819790-22-000010 0 FY2020 FY2021 revenue 57.0M · Revenues, 0001819790-23-000007 FY2021 net income -13.8M · NetIncomeLoss, 0001819790-23-000007 57.0M FY2021 FY2022 revenue 25.8M · Revenues, 0001819790-25-000011 FY2022 net income -62.1M · NetIncomeLoss, 0001819790-25-000011 25.8M FY2022 FY2023 revenue 17.4M · Revenues, 0001819790-26-000019 FY2023 net income -135.9M · NetIncomeLoss, 0001819790-26-000019 17.4M FY2023 FY2024 revenue 183.0M · Revenues, 0001819790-26-000019 FY2024 net income -115.6M · NetIncomeLoss, 0001819790-26-000019 183.0M FY2024 FY2025 revenue 451.4M · Revenues, 0001819790-26-000019 FY2025 net income -66.4M · NetIncomeLoss, 0001819790-26-000019 451.4M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2018 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -21.0% a year FY2020 $26.74 to FY2025 $8.22, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$1.59$8.22-$0.53
Dec 31, 2024 -$3.07$5.97-$2.25
Dec 31, 2023 -$4.62$6.70-$4.05
Dec 31, 2022 -$2.52$7.84-$2.01
Dec 31, 2021 -$0.67$8.11$0.15
Dec 31, 2020 -$4.32$26.74-$3.48
Dec 31, 2019 ---
Dec 31, 2018 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $522.8M
  • − All liabilities $218.7M
  • = Net current asset value $304.1M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $343.4M
  • − Other intangible assets $7.4M
  • = Tangible book value $336.1M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

TARS against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+147%4th of 155 · median +10.5%
Net margin
-4.1%15.3%
-102.9%144th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
4.8%98th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.7057th of 108 · median 0.69
TARS and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
TARS Tarsus Pharmaceuticals, Inc.$682.2M +147%--102.9%-4.8%0.70
RARE Ultragenyx Pharmaceutical Inc.$730.0M +20.2%--71.8%--60.5%-
TMDX TransMedics Group, Inc.$727.6M +37.1%58.6%19.9%26.2%6.1%-
GKOS GLAUKOS Corp$690.3M +32.3%64.8%-24.6%-23.7%5.2%-
MIRM Mirum Pharmaceuticals, Inc.$670.8M +54.7%--134.8%--40.8%-
UFPT UFP Technologies Inc$649.5M +19.5%28.9%11.8%15.8%-0.20
All 162 companies in the group

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2021 · 10-K XBRL, year-end balances

Return on equity -19.3% FY2021: -8.3% net income ÷ equity
Net margin -14.7% FY2021: -24.2% profit per $ of sales: -66.4M ÷ 451.4M
Asset turnover 0.80× FY2021: 0.32× sales per $ of assets: 451.4M ÷ 562.2M
Leverage 1.64× FY2021: 1.07× assets per $ of equity: 562.2M ÷ 343.4M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -102.9% vs 6.8%
  • Return on equity below 15%
    -675.0%
  • A profit in 0 of 6 years
Net margin, FY2020 to FY2025: -24.2% to -14.7%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -7.9× interest expense
  • Debt smaller than equity
    Debt / equity 0.70 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 1.96
  • More cash than debt
    Net cash $297.2M
Debt / equity at each year end, FY2020 to FY2025: 0.00 to 0.21

Cash and shareholders

  • Free cash flow positive in 1 of 6 years
    −$22.3M last year
  • Share count up over 5 years
    +573.1%
Free cash flow, FY2020 to FY2025: -21.6M to -22.3M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

TARS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 8. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue451.4M
FY2018: -FY2019: -FY2020: 0FY2021: 57.0MFY2022: 25.8MFY2023: 17.4MFY2024: 183.0MFY2025: 451.4M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-66.4M
FY2018: -1.3MFY2019: -4.7MFY2020: -26.8MFY2021: -13.8MFY2022: -62.1MFY2023: -135.9MFY2024: -115.6MFY2025: -66.4M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-22.3M
FY2018: -FY2019: -3.8MFY2020: -21.6MFY2021: 3.2MFY2022: -49.5MFY2023: -119.0MFY2024: -84.6MFY2025: -22.3M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-64.0M
FY2018: -FY2019: -3.9MFY2020: -22.4MFY2021: -5.3MFY2022: -63.0MFY2023: -138.8MFY2024: -112.4MFY2025: -64.0M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-1.59
FY2018: -FY2019: -1.98FY2020: -4.32FY2021: -0.67FY2022: -2.52FY2023: -4.62FY2024: -3.07FY2025: -1.59 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Dividend per share0.00
FY2018: -FY2019: 0.00FY2020: 0.00FY2021: 0.00FY2022: 0.00FY2023: 0.00FY2024: 0.00FY2025: 0.00 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares41.8M
FY2018: -FY2019: -FY2020: 6.2MFY2021: 20.6MFY2022: 24.6MFY2023: 29.4MFY2024: 37.6MFY2025: 41.8M FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Product sales, net 451.4M100.0% +151%
License fees and collaboration revenue 00.0% -100%

10-K 0001819790-26-000019, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue--057.0M25.8M17.4M183.0M451.4M
R&D-3.2M18.8M41.7M42.6M50.3M53.4M64.3M
SG&A-1.1M8.2M25.4M44.9M108.7M237.3M427.3M
Operating income--4.3M-27.0M-12.2M-62.7M-143.2M-120.6M-71.0M
Interest expense---02.2M3.3M7.8M8.9M
Pretax income---26.8M-13.8M-62.1M-135.9M-115.6M-64.4M
Income tax-1K1K55K-4K002.1M
Net income-1.3M-4.7M-26.8M-13.8M-62.1M-135.9M-115.6M-66.4M
EPS (diluted)--1.98-4.32-0.67-2.52-4.62-3.07-1.59
Diluted shares--6.2M20.6M24.6M29.4M37.6M41.8M
Depreciation & amortization-37K100K300K326K744K685K855K
EBITDA--4.3M-26.9M-11.9M-62.4M-142.4M-119.9M-70.1M
Operating margin----21.3%-242.9%-820.5%-65.9%-15.7%
Net margin----24.2%-240.5%-778.9%-63.2%-14.7%
Revenue growth-----54.7%-32.4%+949%+147%

Balance sheet

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash2.4M58.0M168.1M171.3M71.7M224.9M94.8M183.6M
Short-term investments--0483K145.4M2.5M196.6M233.6M
Receivables--00016.6M46.8M85.1M
Inventory----03.1M2.6M4.4M
Current assets-58.0M170.7M176.0M225.4M256.1M356.7M522.8M
Property & equipment-154K548K755K957K1.5M2.3M11.7M
Other intangible assets----03.9M8.3M7.4M
Total assets-58.3M172.0M178.9M227.9M265.5M377.0M562.2M
Accounts payable------9.4M16.4M
Current liabilities-819K5.4M11.5M15.4M36.9M80.6M135.7M
Total debt---019.4M29.8M71.8M72.4M
Total liabilities-919K6.0M12.2M35.0M68.5M152.5M218.7M
Shareholders' equity-1.4M-6.0M166.0M166.7M192.9M197.0M224.5M343.4M
Retained earnings--6.0M-32.8M-46.7M-108.8M-244.7M-360.2M-426.6M

Cash flow

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow--3.7M-21.1M3.7M-49.0M-117.5M-83.0M-12.5M
Capital spending-175K456K586K506K1.5M1.6M9.9M
Free cash flow--3.8M-21.6M3.2M-49.5M-119.0M-84.6M-22.3M
Stock-based pay (added back)-18K839K8.5M13.5M19.8M27.8M41.7M
Free cash flow after stock pay--3.9M-22.4M-5.3M-63.0M-138.8M-112.4M-64.0M
Debt raised----20.0M10.0M75.0M0
Investing cash flow--175K-456K-586K-144.6M140.6M-199.2M-42.1M
Financing cash flow-59.4M131.8M21K94.0M130.2M154.7M143.4M
Dividend per share-0.000.000.000.000.000.000.00

Stock-based pay and leases

From EDGAR
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)-18K839K8.5M13.5M19.8M27.8M41.7M
Stock-based pay / revenue---14.8%52.1%113.7%15.2%9.2%
Operating lease cost-100K208K385K569K705K835K1.5M
Operating lease cash paid----680K884K799K858K
Right-of-use assets-126K688K1.1M575K1.9M552K10.1M
Operating lease liabilities-164K831K1.2M889K1.9M608K10.6M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TARS/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.